Do not use persuasive marketing techniques unrelated to scientific content

AI-verifiedwarningFDA guidance · non-bindingRaised as a question — a person decides

Rule

A firm-generated presentation should not use communication techniques that influence HCP decisions based on elements other than scientific content — such as celebrity endorsements, emotional appeals unrelated to the scientific content, gifts, promotional taglines, jingles, or premium offers.

Check

Look for celebrity endorsements, emotionally evocative imagery/language unrelated to the science, gifts, promotional taglines, jingles, or premium offers embedded in or accompanying the presentation. A violation is the presence of any such technique.

Escalate when

Whether an emotional element is 'unrelated to the scientific content' can require judgment.

Where this comes from

Section V, Q5 · page 30. The highlighted words are quoted exactly; a script confirms they appear in the source before the rule can be published.

…on of the recommended disclosures, would be consistent with the enforcement policy outlined in this guidance. In contrast, firm-generated presentations that use communication techniques to encourage the unapproved use of the medical product based on elements other than the communication’s scientific content are outside the scope of the enforcement policy outlined in this guidance.<sup>59,60</sup> Furthermore, in FDA’s experience, when the following communication techniques are used, in most cases, that use is to influence decisions based on elements other than the communication’s substance: celebrity endorsements, emotional appeals unrelated to the scientific content, gifts, promotional tag lines, jingles, and premium offers. For this reason, the enforcement policy outlined in this guidance does not extend to firm-generated presentations of scientific information on unapproved use(s) that use any of the foregoing communication techniques. Additionally, the enforcement policy outlined in this guidance does not extend to firm-generated presentations of scientific information about an unapproved use of the firm’s approved/cleared medical product that include calls to value that pre-judge the benefit(s) of the medical product for individual patients. Examples of calls to value that pre-judge the benefit(s) of the medical product for individual patient…

Open the original at page 30 on fda.gov ↗Read our full copy →

Document: FDA guidance: Communications From Firms to Health Care Providers Regarding Scientific Information on Unapproved Uses of Approved/Cleared Medical Products: Questions and Answers (final)
Version: as retrieved — the publisher does not version this document; the fingerprint below identifies the exact file
Retrieved: 2026-09-21 from www.fda.gov
Fingerprint: a36a07e1efd950b7a2a8f6b3…

FDA guidance describes the agency's current thinking. It is not binding law, and this rule is a recommendation, not an obligation.

Applies when

Audiencehcp

Basisunapproved-use-scientific

How this rule was checked

Citation proven by script and passed an independent verifier running on a different model. Not yet confirmed by a human.

Drafted
claude-code:sonnet · 2026-09-21
Independent verification — revise
claude-code:opus · 2026-09-21
Reviewer's reasons
- The substance is supported by Q5, which states that 'firm-generated presentations that use communication techniques to encourage the unapproved use of the medical product based on elements other than the communication's scientific content are outside the scope of the enforcement policy' and then names the techniques: 'celebrity endorsements, emotional appeals unrelated to the scientific content, gifts, promotional tag lines, jingles, and premium offers.'
- But the quote as selected is purely anaphoric: 'For this reason, the enforcement policy outlined in this guidance does not extend to firm-generated presentations of scientific information on unapproved use(s) that use any of the foregoing communication techniques.' Standing alone it identifies no technique, so it does not on its face establish the list that carries the entire operative content of the rule and check. The supporting text must be in the quote.
- Not overstated: rendering 'the enforcement policy does not extend to' as 'should not use' is equal or weaker in force, and the guidance authority is not exceeded.
- Atomic: one prohibition with an illustrative list of techniques, producing one finding.
- 'judgment' is correct - whether an element is 'unrelated to the scientific content' turns on impression - and the escalate note says so. applies_when, the Q5 locator and 'warning' severity are appropriate.
Revised by the drafter
claude-code:sonnet · 2026-09-21
Independent verification — pass
claude-code:opus · 2026-09-21
Reviewer's reasons
- Q5 states that FDA's enforcement policy 'does not extend to firm-generated presentations of scientific information on unapproved use(s) that use any of the foregoing communication techniques' (celebrity endorsements, emotional appeals unrelated to the scientific content, gifts, promotional tag lines, jingles, premium offers). A 'should not' rule with a warning severity is a faithful rendering of falling outside the enforcement policy; nothing says 'must'.
- The quote is two complete sentences, including the list and the consequence, so it is not a bare fragment.
- The source treats the six techniques as a single list with one consequence ('any of the foregoing'), so one presence check across them is atomic; the rule's general framing matches the preceding sentence about techniques that encourage use 'based on elements other than the communication's scientific content'.
- Judgment is correct: 'unrelated to the scientific content' requires interpretation, and the escalation note says so.

Nearby rules

US-DISC-012 US-DISC-013 US-DISC-014 US-DISC-015 US-SCI-032 US-SCI-033 US-SCI-034 US-SCI-038